Eye Diseases Completed Phase 4 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0030511 (Eye Diseases)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03148132VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROPOther